Cellect Biotechnology (NSDQ:APOP) said it is collaborating with Washington University on a study of its ApoGraft stem cell selection technology for bone marrow transplantations.
This will be the first clinical trial in the U.S. using Tel Aviv, Israel-based Cellect’s ApoGraft, which is designed to prevent acute graft-versus-host disease following bone marrow transplantation. The company previously reported positive safety and tolerability data from an ongoing trial that is being performed outside the U.S., and expects to report additional interim results during the first half of 2019.
Get the full story on our sister site, Medical Design & Outsourcing.
